Around 200 guests including business partners, investors and representatives from pharmaceutical companies were present to witness this historical moment.
To benefit global patients by accelerating the design and manufacturing of innovative biologics that meet global standards. |
| [22-January-2018] |
| HANGZHOU, China, Jan. 22, 2018 /PRNewswire/ -- Hangzhou Just Biotherapeutics (“HJB”), an organization dedicated to expanding global access to important protein therapeutics, today held the grand opening ceremony for its R&D Center and Manufacturing Facility. Around 200 guests including business partners, investors and representatives from pharmaceutical companies were present to witness this historical moment. Jonathan Y. Zhao, Founder and CEO of HJB, delivered a speech at the opening ceremony. He reviewed the progress HJB has made since its establishment, and stressed that “HJB has reached another important milestone. This is a great step towards our mission of expanding global access to biotherapeutics. We will further leverage the 3rd-generation biologics platform to develop and manufacture high quality biologics for patients around the world.” Jonathan Y. Zhao, Jim Thomas and two other senior executives from Amgen co-founded Just Biotherapeutics Inc. in Seattle in 2015. Subsequently, its sister company, HJB, was established in China in August 2016. So far, both companies employ nearly 200 scientists and engineers. Over the past two years, HJB has secured a total of USD 67 million in financing from Lilly Asia Ventures, ARCH Venture Partners, Temasek, Taikang, HEDA and other investors, and has grown rapidly. HJB completed the 140,000 sq.ft R&D Center and GMP Manufacturing Facility which will supply the global market with clinical and commercial product. View original content:http://www.prnewswire.com/news-releases/hangzhou-just-biotherapeutics-opens-rd-center-and-gmp-manufacturing-facility-to-develop-biologic-medicines-globally-300585757.html SOURCE Hangzhou Just Biotherapeutics, Ltd. |
